William Blair & Company
DMAC icon

William Blair & Company’s DiaMedica Therapeutics DMAC Stock Holding History

William Blair & Company’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$69K – 1728
2020
Q2 		$69K Hold
10,000
– – ﹤0.01% 1411
2020
Q1 		$28K Hold
10,000
– – ﹤0.01% 1447
2019
Q4 		$49K Buy
+10,000
New +$31.1K ﹤0.01% 1488

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

William Blair & Company's DMAC Position: Q3 2020 in Review

William Blair & Company sold out of DiaMedica Therapeutics (DMAC) in Q3 2020, closing a stake of 10,000 shares — an estimated $69K sold.

William Blair & Company first reported a position in DMAC in Q4 2019 and held it in 3 quarters. The position peaked at $69K in Q2 2020. 33 funds tracked by Wall St. Rank hold DMAC as of Q3 2020.

  • William Blair & Company reported no remaining DiaMedica Therapeutics position as of Q3 2020 after selling out during the quarter.
  • William Blair & Company sold 10,000 DiaMedica Therapeutics shares in Q3 2020, an estimated $69K.
  • William Blair & Company first reported a position in DiaMedica Therapeutics in Q4 2019 and held it in 3 quarters.
  • William Blair & Company's DiaMedica Therapeutics position peaked at $69K in Q2 2020.
  • 33 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2020.

Based on William Blair & Company's 13F filing for Q3 2020, filed 6 Nov 2020.